RespireRx Pharmaceuticals Inc

RespireRx Pharmaceuticals — Noble Financial Capital Markets' Twelfth Annual Investor/Equity Conference (NobleCon12) (January 2016)

35 slides from RespireRx Pharmaceuticals's conference presentation, Jan 19, 2016

  1. Slide 1: RespireRx Pharmaceuticals - Medicines for Respiratory Diseases

    Slide 1: RespireRx Pharmaceuticals - Medicines for Respiratory Diseases

    DN RespireRx Pharmaceuticals Inc Jeff E. Margolis, VP, Treasurer & Secretary January 20, 2016 NOBLE FINANCIAL CAPITAL MARKETS’ ‘TWELFTH ANNUAL INVESTOR/EQUITY CONFERENCE ~ NOBLECON12 Medicines for Respiratory Diseases i:

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements CG) RespireRx Pharmaceuticals Inc The matters discussed in this presentation that are not historical facts are "forward-looking statements." Forward-looking statements include, but are not limited to, statements containing the words "believes," “anticipates,” "intends," "e

  3. Slide 3: Breath

    Slide 3: Breath

    Breath GR RespireRx "Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit the same word means both breath and life." muna Abbot George Burke

  4. Slide 4: The RespireRx Story: Innovative Medicines for Respiratory Diseases

    Slide 4: The RespireRx Story: Innovative Medicines for Respiratory Diseases

    The RespireRx Story: Innovative Medicines for Respiratory Diseases CG) RespireRx Pharmaceuticals Inc o Two drug platforms o Three Phase 2 or Phase 2-ready programs o One pre-clinical program o Blockbuster markets o IP protection with the ability to add additional IP o Multiple opportunities for stra

  5. Slide 5: Company Focus

    Slide 5: Company Focus

    Company Focu QRespireRx Sleep Apneas ° * Dronabinol for Obstructive Sleep Apnea (OSA) » Ampakines for Central Sleep Apnea (CSA) o Drug-induced Respiratory Depression (RD) - Ampakines « Semi-acute use — post-surgical pain management with opioids * Acute use — surgical anesthesia/sedation = Chronic us

  6. Slide 6: id Re

    Slide 6: id Re

    id Re Compound Dronabinol Cbstnetive Sleep Apnea Central Stoop Apnea: pind. induced RD Spin DamagalPompe mmbination Formulation Onin for Reduced RD Drug induced Resp Deprossian (injedato) Pre-clinical pireRx SJ Pharmaceuticals Inc

  7. Slide 7: Sleep Apnea

    Slide 7: Sleep Apnea

    Sleep Apnea AQ RespireRx o Sleep Apnea = Repetitive episodes of airflow cessation (apnea) or reduction (hypopnea) for more than 10 seconds during sleep = Three types: Obstructive, Central & Mixed co The Sleep Apnea Market is Large = 18 million U.S. adults suffer from moderate or severe sleep apneas

  8. Slide 8: Obstructive Sleep Apnea (OSA)

    Slide 8: Obstructive Sleep Apnea (OSA)

    Obstructive Sleep Apnea (OSA) GQ RespireRx Pharmaceuticals Inc o Obstructive Sleep Apnea (OSA): a decrease or complete halt in airflow during sleep = Induced by relaxation of muscles during sleep * Soft tissue in back of throat collapses and obstructs upper airway o Significant morbidity due to stro

  9. Slide 9: CPAP Efficacy is Severely Limited by Patient Compliance

    Slide 9: CPAP Efficacy is Severely Limited by Patient Compliance

    CPAP Efficacy is Severly Limited by Patient Compliance OS o Works as an air splint to keep upper airway open during sleep o 30% of diagnosed patients never initiate CPAP treatment when prescribed a machine o Over 50% of patients stop using CPAP in the first year o Many CPAP users wear the device for

  10. Slide 10: Dronabinol

    Slide 10: Dronabinol

    AX RespireRx o Mechanism of Action * Dronabinol is (D-9)THC, a cannabinoid agonist o Background * Schedule III drug available by prescription, with a low risk of addiction = Approved for the treatment of anorexia in AIDS patients and nausea and vomiting in cancer patients undergoing chemotherapy = P

  11. Slide 11: Completed Phase 2A Trial of Dronabinol in OSA

    Slide 11: Completed Phase 2A Trial of Dronabinol in OSA

    Completed Phase 2A Trial of binol in OS, CA Respirerx o Randomized, double-blind, placebo-controlled dose escalation study in 22 patients with OSA o Placebo (N=5) or dronabinol (N=17) for 21 days * 2.5, 5 and 10 mg/night studied with weekly dose escalation o Overnight polysomnogram (PSG) at baseline

  12. Slide 12: Dronabinol Proven to Reduce Apnea in OSA Subjects

    Slide 12: Dronabinol Proven to Reduce Apnea in OSA Subjects

    abinol Proven to Reduce Apnea in OSA Subjects RespireRx Pharmaceuticals Inc P=0.17 Dronabinol Placebo P<0.01 30% 40% Reduction in Sleep Apnea 12

  13. Slide 13: Apnea Suppression as a Function of Dose and Time

    Slide 13: Apnea Suppression as a Function of Dose and Time

    nea Suppression as a Functi jose ime BW RespireRx Pharmaceuticals inc ist Half 2nd Halt AAHI versus Baseline Bee eb be eae ne17 ne 13 m8 The plasma half-life of dronabinol is 2-4 hours.

  14. Slide 14: Dronabinol Phase 2B Clinical Trial in OSA

    Slide 14: Dronabinol Phase 2B Clinical Trial in OSA

    binol Phase 2B Clinical Trial in OSA AX RespireRx o Sponsored and led by U of Illinois o 4 major centers, fully funded by NIH o Potentially pivotal for an accelerated NDA © 120 subjects (40/group, 6 wks dosing) o Doses: Placebo, 2.5 mg, 10 mg qd o Data expected Q3/2016 o Plan to meet with FDA after

  15. Slide 15: Protecting Dronabinol in the Market

    Slide 15: Protecting Dronabinol in the Market

    Protecting Dronabinol in the Market a RespireRx Pharmaceuticals inc o License to issued Method-of-Use patent for dronabinol in OSA = Expires in 2025 o Schedule III drug: off-label use monitored by US government, discouraging generic manufacturers from selling off-label o Off-label use of generics an

  16. Slide 16: The Dronabinol Opportunity

    Slide 16: The Dronabinol Opportunity

    The Dronabino! Opportunity Ad RespireRx Pharmaceuticals inc Impact on Patient Commercial Opportunity First pharmacotherapeutic available for OSA Ease of Use/Better Patient Compliance Low cost Safe and effective Potential for better cardiovascular outcomes Changes the nature of OSA treatment Broadly

  17. Slide 17: Central Sleep Apnea

    Slide 17: Central Sleep Apnea

    Central Sleep Apnea GQ RespireRx Pharmaceuticals inc o Caused by a lack of drive from the brain to breathe during sleep o Manifestations of CSA = 70% of chronic narcotic users = Up to 40% of heart failure patients = 5% of sleep apnea patients are idiopathic o No therapeutic or device is approved for

  18. Slide 18: The Severity of CSA is Correlated with Increased Mortality in HF Patients

    Slide 18: The Severity of CSA is Correlated with Increased Mortality in HF Patients

    The Severity of CSA is Correlated with Increased Mortality Respirer' in HF Patients cael beats Reducing Central Sleep Apnea May Reduce Mortality in Heart Failure Patients (88 A kes than S per hour ‘eee AM equal x grater than Spr hour ‘Survival % eeeeeeease f cr Dae HOD Own ww mw em Months: PERI 024

  19. Slide 19: Ampakines - A Novel Class of Drugs

    Slide 19: Ampakines - A Novel Class of Drugs

    AMPAKINES — A NOVEL S OF DRUGS CG )RespireRx AMPA Receptors Mediate Synaptic Transmission in the Brain o Glutamate is the major excitatory neurotransmitter in the CNS o Fast excitatory transmission is mediated by AMPA-type glutamate receptors o Ampakines are positive, allosteric modulators of the ce

  20. Slide 20: Ampakines: Novel Treatment for Respiratory Depression

    Slide 20: Ampakines: Novel Treatment for Respiratory Depression

    AMPAKINES lovel Treatment for Respiratory Depressio: “ eax RespireRx Pharmaceuticals Ine Initial research conducted by Dr. J. Greer, U. Alberta Renet al, Anesthesiology. 110:1364-1370, 2009 Neurons in this brainstem region control inspiratory breathing rhythm PreBotC neurons use AMPA receptors for s

  21. Slide 21: CX1739: A Third Generation, Oral Ampakine in Phase 2

    Slide 21: CX1739: A Third Generation, Oral Ampakine in Phase 2

    X1739: A Third Generation, Oral Ampakine in Phase 2 G®)RespireRx Pharmaceuticals inc o Targeted Indications = Central Sleep Apnea (CSA) = Reversal and prevention of opioid-induced Respiratory Depression (RD) = Combination formulation with an opioid for treatment of chronic pain © Stage of Developmen

  22. Slide 22: CX1739: IND Status

    Slide 22: CX1739: IND Status

    CX1739: IND Status W RespireRx Pharmaceuticals Inc © IND * Opioid induced respiratory depression study = Submitted to FDA on September 18, 2015 © FDAnoted two deficiencies = Myocardial Histology V FDA requested tissue analysis for all rats at all doses v Analysis completed v No drug-related histopat

  23. Slide 23: CX1739: Completed Phase 2A in Sleep Apnea

    Slide 23: CX1739: Completed Phase 2A in Sleep Apnea

    RespireRx Pharmaceuticals inc CX1739: Completed Phase 2A in Sleep Apnea Design Randomized, double-blind, placebo-controlled study Population | 20 adults with all types of moderate to severe sleep apnea (16 given CX1739; 4 given Placebo) Dosing Each subject received either placebo or a sinale dose of

  24. Slide 24: Patient Selection: CX1739 Was More Effective in Treating Mixed and Central Sleep Apneas

    Slide 24: Patient Selection: CX1739 Was More Effective in Treating Mixed and Central Sleep Apneas

    Patient Selection: CX1739 Was More Effective in = Treating Mixed and Central Sleep Apneas )RespireRx Obstructive Apneas Mixed Apneas Central Apnea ‘0 * ge ar: 7 & oe se & ¢ ra e & (Events/hr) SaBRss Apnea Index Apnea Index (Events/hr) Apnea Index (Events/hr) 24

  25. Slide 25: Drug-Induced Respiratory Depression

    Slide 25: Drug-Induced Respiratory Depression

    iced Respiratory Depressi CA RespireRx RD is the most frequent lethal side effect of opioid use o Acute and Semi-Acute Use of opioids = ~25M patients/year at risk for RD (hospitalized, peri- and post-surgical opioid patients) o Chronic Opioid Use = Use of Ampakines in combination with other drugs to

  26. Slide 26: Ampakines Prevent Opioid-Induced Respiratory Depression in Humans

    Slide 26: Ampakines Prevent Opioid-Induced Respiratory Depression in Humans

    Ampakines Prevent Opi nduced Respiratory Depression in Humans © Two clinical studies in normal, healthy volunteers with CX717, a second-generation Ampakine o Moderate Respiratory Depression was induced experimentally by infusion of the opioid, Alfentanil o Respiratory and analgesia end-points were m

  27. Slide 27: CX717 Prevents Opioid-Induced Respiratory Depression in Humans

    Slide 27: CX717 Prevents Opioid-Induced Respiratory Depression in Humans

    CX717 events Opioid-induced Respiratory a Depression in Humans CG) RespireRx Pharmaceuticals inc (Placebo meaex7i7 “Pp <0.01 NS - Not Significant Breaths/min Data are expre Ne 18 and Baseline +Affentanil +Naloxone Alfentanil reduced breathing rate & produced Respiratory Depression CX717 maintains re

  28. Slide 28: CX717 Maintains the Analgesic Properties of Opioids

    Slide 28: CX717 Maintains the Analgesic Properties of Opioids

    CX717 Maintains the Analgesic Properties of Opioids Without Affecting Rescue Therapy BA RespireRx Analgesia 20. [Placebo p15 mmcx717 2 FA 2 10. aN. 3B £ & os. Delivery of a electical stimulation to finger Baseline +Alfentanil_+Naloxone A\fentanil reduced the pain sensitivity (produced analgesia) res

  29. Slide 29: 1A RespireRx

    Slide 29: 1A RespireRx

    1A RespireRx CAN) pharmaceuticals ine Compound Indication Dronabinol Cbstnetive Sleep Apnea Central Sleep Apnea pind. induced RD sination poids for Reduced RD Drug induced Ress Deprossian (injedato)

  30. Slide 30: RespireRx

    Slide 30: RespireRx

    RespireRx Pharmaceuticals Inc

  31. Slide 31: Non-Dilutive Finance

    Slide 31: Non-Dilutive Finance

    Non-Dilutive Finance + Government Sponsored efforts e Drug abuse and addiction — initially cocaine and amphetamines Research and development program with NIDA NIDA contracts with specialist labs and pays for studies Company provides compounds and retains all rights e Neurological and Psychiatric - A

  32. Slide 32: Capital Structure & Market

    Slide 32: Capital Structure & Market

    Capital Structure (in res) & Market Total As of September 30, 2015 RespireRx Pharmaceuticals Inc Common Stock | 477,221 Common Stock Equivalents of all Convertibles (Preferred Stock and Convertible Notes) 95,934 ‘Common Stock Equivalents of all Options and 380,247 Warrants: Total 953,402 a Closing p

  33. Slide 33: Management and Directors

    Slide 33: Management and Directors

    agement an James Manuso Arnold Lippa Jeff Margolis Robert Weingarten Richard Purcell Katie MacFarlane James Sapirstein John Greer Directors aw President, CEO & Vice Chairman CSO & Chairman VP, Secretary/Treasurer, Director CFO, Director Senior VP, R& D Director CCO Agile Therapeutics Director CEO Co

  34. Slide 34: The RespireRx Story: Innovative Medicines for Respiratory Diseases

    Slide 34: The RespireRx Story: Innovative Medicines for Respiratory Diseases

    The RespireRx Story: Innovative Medicines for e Respiratory Diseases GQ)RespireRx o Twodrug platforms o Three Phase 2 or Phase 2-ready programs o One pre-clinical program o Blockbuster markets o IP protection with the ability to add additional IP o Multiple opportunities for strategic collaborations

  35. Slide 35: RespireRx Pharmaceuticals - Medicines for Respiratory Diseases

    Slide 35: RespireRx Pharmaceuticals - Medicines for Respiratory Diseases

    DN RespireRx Pharmaceuticals Inc Jeff E. Margolis, VP, Treasurer & Secretary January 20, 2016 NOBLE FINANCIAL CAPITAL MARKETS’ ‘TWELFTH ANNUAL INVESTOR/EQUITY CONFERENCE ~ NOBLECON12 Medicines for Respiratory Diseases 35

Source: SEC EDGAR · 8-K filed Jan 19, 2016

More decks from RespireRx Pharmaceuticals Inc